Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Multicenter, Open Label, Phase II Study of Bendamustine and Rituximab followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe).

Lansigan F, Costa CA, Zaki B, Yen S, Winer EP, Ryan H, Findley D, Metzler S, Shaw L, Toaso B, Mackenzie TA, Chen Y, Beaven AW.

Clin Cancer Res. 2019 Jun 26. pii: clincanres.3755.2018. doi: 10.1158/1078-0432.CCR-18-3755. [Epub ahead of print]

PMID:
31243122
2.

Accuracy of Acid-Base Diagnoses Using the Central Venous Blood Gas in the Medical Intensive Care Unit.

Schrauben SJ, Negoianu D, Costa C, Cohen RM, Goldfarb S, Fuchs BD, Berns JS.

Nephron. 2018;139(4):293-298. doi: 10.1159/000488501. Epub 2018 Apr 12.

3.

C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.

Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evens AM, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ.

Cancer. 2017 Nov 15;123(22):4411-4418. doi: 10.1002/cncr.30895. Epub 2017 Jul 27. Erratum in: Cancer. 2018 Feb 15;124(4):867. Evans, Andrew [corrected to Evens, Andrew M].

4.

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.

Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD.

J Clin Oncol. 2017 Jul 10;35(20):2260-2267. doi: 10.1200/JCO.2017.72.2157. Epub 2017 May 5.

5.

Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.

Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M.

Am J Hematol. 2017 Feb;92(2):161-170. doi: 10.1002/ajh.24615.

6.

Study and characterization of the crest module design: A 3D finite element analysis.

Costa C, Peixinho N, Silva JP, Carvalho S.

J Prosthet Dent. 2015 Jun;113(6):541-7. doi: 10.1016/j.prosdent.2014.12.008. Epub 2015 Mar 18.

PMID:
25794909
7.

No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies.

da Costa CE, Szuhai K, van Eijk R, Hoogeboom M, Sciot R, Mertens F, Björgvinsdóttir H, Debiec-Rychter M, de Krijger RR, Hogendoorn PC, Egeler RM, Annels NE.

Genes Chromosomes Cancer. 2009 Mar;48(3):239-49. doi: 10.1002/gcc.20634.

PMID:
19051326
8.

Post-zygotic reproductive isolation between sympatric taxa in the Chamaecrista desvauxii complex (Leguminosae-Caesalpinioideae).

Costa CB, Lambert SM, Borba EL, de Queiroz LP.

Ann Bot. 2007 Apr;99(4):625-35. Epub 2007 Mar 1.

9.

Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis.

da Costa CE, Annels NE, Faaij CM, Forsyth RG, Hogendoorn PC, Egeler RM.

J Exp Med. 2005 Mar 7;201(5):687-93.

10.

Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis.

Annels NE, Da Costa CE, Prins FA, Willemze A, Hogendoorn PC, Egeler RM.

J Exp Med. 2003 May 19;197(10):1385-90. Epub 2003 May 12.

Supplemental Content

Loading ...
Support Center